7.65
전일 마감가:
$7.73
열려 있는:
$7.72
하루 거래량:
214.01K
Relative Volume:
1.29
시가총액:
$163.10M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-1.5455
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+16.08%
1개월 성능:
+6.55%
6개월 성능:
+47.68%
1년 성능:
-47.89%
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ENTA
Enanta Pharmaceuticals Inc
|
7.63 | 148.78M | 66.59M | -104.93M | -96.48M | -4.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.51 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.47 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.96 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
574.44 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.06 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
2022-12-09 | 개시 | H.C. Wainwright | Buy |
2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
2021-10-07 | 개시 | Jefferies | Buy |
2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
2020-11-24 | 개시 | Evercore ISI | Underperform |
2020-08-28 | 재개 | ROTH Capital | Buy |
2020-08-26 | 개시 | Piper Sandler | Overweight |
2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2019-05-24 | 개시 | Wolfe Research | Outperform |
2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
2018-12-13 | 개시 | Berenberg | Hold |
2018-06-06 | 개시 | ROTH Capital | Buy |
2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 재확인 | Barclays | Underweight |
2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
What analysts say about Enanta Pharmaceuticals Inc. stockStrong return on investment - PrintWeekIndia
What drives Enanta Pharmaceuticals Inc. stock priceFree Investment Case Studies - Autocar Professional
Is Enanta Pharmaceuticals Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Enanta Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com
why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace
how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser
What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser
How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st
(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria
AbbVie Secures FDA Approval to Expand Mavyret’s Label - Yahoo Finance
ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World
Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus
Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):